{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:44:43Z","timestamp":1774327483482,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["J007412"],"award-info":[{"award-number":["J007412"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5489-4","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T14:03:36Z","timestamp":1553522616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A \u2013 C-Raf"],"prefix":"10.1186","volume":"19","author":[{"given":"Connor M.","family":"Blair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola M.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce H.","family":"Littman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank W.","family":"Marcoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-6316","authenticated-orcid":false,"given":"George S.","family":"Baillie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"5489_CR1","unstructured":"Melanoma UK Statistics. \n                    http:\/\/www.melanomauk.org.uk\/about_melanoma\/statistics\/\n                    \n                   Available 23 Apr 2017."},{"issue":"6892","key":"5489_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature."},{"key":"5489_CR3","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1158\/1078-0432.CCR-1169-3","volume":"10","author":"M Shinozaki","year":"2004","unstructured":"Shinozaki M, Fujimoto A, Morton DL, Hoon DSB. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004;10:1753\u20137.","journal-title":"Clin Cancer Res"},{"key":"5489_CR4","unstructured":"Lovly C, Pao W, Sosman J. BRAF c.1799T>a (V600E) mutation in melanoma. My Cancer. 2015; \n                    https:\/\/www.mycancergenome.org\/content\/disease\/melanoma\/braf\/54\/\n                    \n                   Available 29 Apr 2017."},{"issue":"8","key":"5489_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, et al. Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta - Molecular Cell Research. 2007;1773(8):1263\u201384.","journal-title":"Biochimica et Biophysica Acta - Molecular Cell Research"},{"issue":"9","key":"5489_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809\u201319.","journal-title":"N Engl J Med"},{"issue":"33","key":"5489_CR7","doi-asserted-by":"publisher","first-page":"14903","DOI":"10.1073\/pnas.1008990107","volume":"107","author":"EW Joseph","year":"2010","unstructured":"Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci. 2010;107(33):14903\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"5489_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/ITT.S134842","volume":"7","author":"B Domingues","year":"2018","unstructured":"Domingues B, Lopes JM, Soares P, P\u00f3pulo H. Melanoma treatment in review. ImmunoTargets Ther. 2018;7:35\u201349.","journal-title":"ImmunoTargets Ther"},{"issue":"44","key":"5489_CR9","doi-asserted-by":"publisher","first-page":"78174","DOI":"10.18632\/oncotarget.19836","volume":"8","author":"M Griffin","year":"2017","unstructured":"Griffin M, Scotto D, Josephs DH, Mele S, Crescioli S, Bax HJ, et al. BRAF inhibitors : resistance and the promise of combination treatments for melanoma. Oncotarget. 2017;8(44):78174\u201392.","journal-title":"Oncotarget."},{"issue":"2","key":"5489_CR10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","volume":"23","author":"R Halaban","year":"2010","unstructured":"Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, et al. PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells. Pigment Cell Melanoma Res. 2010;23(2):190\u2013200.","journal-title":"Pigment Cell Melanoma Res"},{"key":"5489_CR11","doi-asserted-by":"publisher","first-page":"26803","DOI":"10.1038\/srep26803","volume":"6","author":"YT Oh","year":"2016","unstructured":"Oh YT, Deng J, Yue P, Sun SY. Paradoxical activation of MEK\/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells. Sci Rep. 2016;6:26803.","journal-title":"Sci Rep"},{"issue":"7","key":"5489_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nrclinonc.2013.83","volume":"10","author":"GT Gibney","year":"2013","unstructured":"Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KSM. Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013;10(7):390\u20139.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7282","key":"5489_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7282):427\u201330.","journal-title":"Nature."},{"issue":"2","key":"5489_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","volume":"140","author":"SJ Heidorn","year":"2010","unstructured":"Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209\u201321.","journal-title":"Cell."},{"key":"5489_CR15","doi-asserted-by":"crossref","unstructured":"Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal. 2014;7(318).","DOI":"10.1126\/scisignal.2004815"},{"issue":"19","key":"5489_CR16","doi-asserted-by":"publisher","first-page":"9483","DOI":"10.1158\/0008-5472.CAN-05-4227","volume":"66","author":"N Dumaz","year":"2006","unstructured":"Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006;66(19):9483\u201391.","journal-title":"Cancer Res"},{"issue":"5","key":"5489_CR17","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nsmb.2022","volume":"18","author":"A Marquette","year":"2011","unstructured":"Marquette A, Andr\u00e9 J, Bagot M, Bensussan A, Dumaz N. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol. 2011;18(5):584\u201391.","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"5489_CR18","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1128\/MCB.26.6.2262-2272.2006","volume":"26","author":"LK Rushworth","year":"2006","unstructured":"Rushworth LK, Hindley AD, O\u2019Neill E, Kolch W. Regulation and role of Raf-1\/B-Raf Heterodimerization. Mol Cell Biol. 2006;26(6):2262\u201372.","journal-title":"Mol Cell Biol"},{"key":"5489_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/bjc.2017.399","volume":"118","author":"DE Durrant","year":"2018","unstructured":"Durrant DE, Morrison DK. Targeting the Raf kinases in human cancer: the Raf dimer dilemma. Vol. 118. Br J Cancer. 2018;118:3\u20138.","journal-title":"Br J Cancer"},{"issue":"16","key":"5489_CR20","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1073\/pnas.1303004110","volume":"110","author":"KM Brown","year":"2013","unstructured":"Brown KM, Day JP, Huston E, Zimmermann B, Hampel K, Christian F, et al. Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proc Natl Acad Sci. 2013;110(16):1533\u201342.","journal-title":"Proc Natl Acad Sci"},{"issue":"16","key":"5489_CR21","doi-asserted-by":"publisher","first-page":"6248","DOI":"10.1073\/pnas.1303920110","volume":"110","author":"DH Maurice","year":"2013","unstructured":"Maurice DH. PDE8A runs interference to limit PKA inhibition of Raf-1. Proc Natl Acad Sci. 2013;110(16):6248\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"5489_CR22","doi-asserted-by":"crossref","unstructured":"Min DH, Mrksich M. Peptide arrays: towards routine implementation. Curr Opin Chem Biol. 2004;8:554\u20138.","DOI":"10.1016\/j.cbpa.2004.08.007"},{"issue":"5","key":"5489_CR23","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1039\/c0cs00029a","volume":"40","author":"C Katz","year":"2011","unstructured":"Katz C, Levy-Beladev L, Rotem-Bamberger S, Rito T, R\u00fcdiger SGD, Friedler A. Studying protein\u2013protein interactions using peptide arrays. Chem Soc Rev. 2011;40(5):2131.","journal-title":"Chem Soc Rev"},{"key":"5489_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cellsig.2017.08.007","volume":"40","author":"CP Basole","year":"2017","unstructured":"Basole CP, Nguyen RK, Lamothe K, Vang A, Clark R, Baillie GS, et al. PDE8 controls CD4+T cell motility through the PDE8A-Raf-1 kinase signaling complex. Cell Signal. 2017;40:62\u201372.","journal-title":"Cell Signal"},{"issue":"12","key":"5489_CR25","first-page":"407","volume":"57","author":"BH Littman","year":"2016","unstructured":"Littman BH, Marcoux FW, Jamison JA. Efficacy of PPL-003 and the role of NF\u03baB activation in a rat model of dry eye disease. Invest Ophthalmol Vis Sci. 2016;57(12):407.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"5489_CR26","first-page":"1896","volume":"57","author":"JT Rosenbaum","year":"2016","unstructured":"Rosenbaum JT, Littman BH, Marcoux FW, Jamison JA. Efficacy of PPL-003 and inhibition of NF\u03baB activation in a rabbit mycobacterial antigen-induced uveitis model. Invest Ophthalmol Vis Sci. 2016;57(12):1896.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"5489_CR27","first-page":"460","volume":"58","author":"BH Littman","year":"2017","unstructured":"Littman BH, Jamison JA, Ochoa R. Rabbit safety of topical PPL-003: a cell penetrating peptide inhibitor of NFkB for dry eye disease. Invest Ophthalmol Vis Sci. 2017;58(8):460.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"5489_CR28","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1128\/MCB.00883-10","volume":"31","author":"DF Anthony","year":"2011","unstructured":"Anthony DF, Sin YY, Vadrevu S, Advant N, Day JP, Byrne AM, et al. \u03b2-Arrestin 1 inhibits the GTPase-activating protein function of ARHGAP21, promoting activation of RhoA following angiotensin II type 1A receptor stimulation. Mol Cell Biol. 2011;31(5):1066\u201375.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"5489_CR29","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/bjc.2014.22","volume":"110","author":"DJP Henderson","year":"2014","unstructured":"Henderson DJP, Byrne A, Dulla K, Jenster G, Hoffmann R, Baillie GS, et al. The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. Br J Cancer. 2014;110(5):1278\u201387.","journal-title":"Br J Cancer"},{"key":"5489_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12964-015-0094-x","volume":"13","author":"YY Sin","year":"2015","unstructured":"Sin YY, Martin TP, Wills L, Currie S, Baillie GS. Small heat shock protein 20 (Hsp20) facilitates nuclear import of protein kinase D 1 (PKD1) during cardiac hypertrophy. Cell Commun Signal. 2015;13:16.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"5489_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/2211-5463.12156","volume":"7","author":"RT Cameron","year":"2017","unstructured":"Cameron RT, Whiteley E, Day JP, Parachikova AI, Baillie GS. Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1\u201342-mediated cytotoxicity. FEBS Open Bio. 2017;7(1):64\u201373.","journal-title":"FEBS Open Bio."},{"key":"5489_CR32","doi-asserted-by":"crossref","unstructured":"Day JP, Whiteley E, Freeley M, Long A, Malacrida B, Kiely P, et al. RAB40C regulates RACK1 stability via the ubiquitin \u2013 proteasome system. Futur Scii OA. 2018;4(7).","DOI":"10.4155\/fsoa-2018-0022"},{"key":"5489_CR33","doi-asserted-by":"publisher","first-page":"8896","DOI":"10.1002\/anie.201412070","volume":"54","author":"M Pelay-Gimeno","year":"2015","unstructured":"Pelay-Gimeno M, Glas A, Koch O, Grossmann TN. Structure-based Design of Inhibitors of protein-protein interactions: mimicking peptide binding epitopes. Angew Chem Int Ed Engl. 2015;54:8896\u2013927.","journal-title":"Angew Chem Int Ed Engl."},{"key":"5489_CR34","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1039\/C5SC02321A","volume":"6","author":"HJ Zhong","year":"2015","unstructured":"Zhong HJ, Lu L, Leung KH, Wong CCL, Peng C, Yan SC, Ma DL, Cai Z, David Wang HM, Leung CH. An iridium (iii)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent. Chem Sci. 2015;6:5400\u20138.","journal-title":"Chem Sci"},{"key":"5489_CR35","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1021\/jm900159g","volume":"52","author":"EV Kurenova","year":"2009","unstructured":"Kurenova EV, Hunt DL, He D, Magis AT, Ostrov DA, Cance WG. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem. 2009;52:4716\u201324.","journal-title":"J Med Chem"},{"key":"5489_CR36","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.4161\/15384101.2015.941760","volume":"13","author":"E Kurenova","year":"2014","unstructured":"Kurenova E, Ucar D, Liao J, Yemma M, Gogate P, Bshara W, Sunar U, Seshadri M, Hochwald SN, Cance WG. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Cell Cycle. 2014;13:2542\u201353.","journal-title":"Cell Cycle"},{"key":"5489_CR37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1089\/adt.2018.858","volume":"16","author":"AT Fancher","year":"2018","unstructured":"Fancher AT, Hua Y, Camarco DP, Close DA, Strock CJ, Johnston PA. High-content screening campaign to identify compounds that inhibit or disrupt androgen receptor-transcriptional intermediary factor 2 protein-protein interactions for the treatment of prostate Cancer. Assay Drug Dev Technol. 2018;16:297\u2013319.","journal-title":"Assay Drug Dev Technol"},{"key":"5489_CR38","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/anie.201711828","volume":"57","author":"S Xu","year":"2018","unstructured":"Xu S, Aguilar A, Xu T, Zheng K, Huang L, Stuckey J, Chinnaswamy K, Bernard D, Fernandez-Salas E, Liu L, Wang M, McEachern D, Przybranowski S, Foster C, Wang S. Design of the First-in-Class, highly potent irreversible inhibitor targeting the Menin-MLL protein-protein interaction. Angew Chem Int Ed Engl. 2018;57:1601\u20135.","journal-title":"Angew Chem Int Ed Engl"},{"key":"5489_CR39","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1021\/acs.jmedchem.8b00071","volume":"61","author":"D Borkin","year":"2018","unstructured":"Borkin D, Klossowski S, Pollock J, Miao H, Linhares BM, Kempinska K, Jin Z, Purohit T, Wen B, He M, Sun D, Cierpicki T, Grembecka J. Complexity of blocking bivalent protein-protein interactions: development of a highly potent inhibitor of the Menin-mixed-lineage leukemia interaction. J Med Chem. 2018;61:4832\u201350.","journal-title":"J Med Chem"},{"key":"5489_CR40","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1021\/acs.biochem.7b00732","volume":"57","author":"T Sameshima","year":"2018","unstructured":"Sameshima T, Yamamoto T, Sano O, Sogabe S, Igaki S, Sakamoto K, Ida K, Gotou M, Imaeda Y, Sakamoto J, Miyahisa I. Discovery of an irreversible and cell-active BCL6 inhibitor selectively targeting Cys53 located at the protein-protein interaction Interface. Biochemistry. 2018;57:1369\u201379.","journal-title":"Biochemistry."},{"key":"5489_CR41","doi-asserted-by":"publisher","first-page":"e0176599","DOI":"10.1371\/journal.pone.0176599","volume":"12","author":"A Benavides-Serrato","year":"2017","unstructured":"Benavides-Serrato A, Lee J, Holmes B, Landon KA, Bashir T, Jung ME, Lichtenstein A, Gera J. Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma. PLoS One. 2017;12:e0176599.","journal-title":"PLoS One"},{"key":"5489_CR42","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1039\/b821676b","volume":"26","author":"RC Clark","year":"2009","unstructured":"Clark RC, Lee SY, Searcey M, Boger DL. The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction. Nat Prod Rep. 2009;26:465\u201377.","journal-title":"Nat Prod Rep"},{"key":"5489_CR43","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1349-7006.2007.00723.x","volume":"99","author":"T Okamoto","year":"2008","unstructured":"Okamoto T. Molecular docking analysis of the protein-protein interaction between RelA-associated inhibitor and tumor suppressor protein p53 and its inhibitory effect on p53 action. Cancer Sci. 2008;99:615\u201322.","journal-title":"Cancer Sci"},{"key":"5489_CR44","doi-asserted-by":"publisher","first-page":"12102","DOI":"10.1021\/jacs.8b06738","volume":"140","author":"CA Rhodes","year":"2018","unstructured":"Rhodes CA, Dougherty PG, Cooper JK, Qian Z, Lindert S, Wang QE, Pei D. Cell-permeable bicyclic peptidyl inhibitors against NEMO-IkappaB kinase interaction directly from a combinatorial library. J Am Chem Soc. 2018;140:12102\u201310.","journal-title":"J Am Chem Soc"},{"key":"5489_CR45","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.chembiol.2017.06.013","volume":"24","author":"L Dietrich","year":"2017","unstructured":"Dietrich L, Rathmer B, Ewan K, Bange T, Heinrichs S, Dale TC, Schade D, Grossmann TN. Cell permeable stapled peptide inhibitor of Wnt signaling that targets beta-catenin protein-protein interactions. Cell Chem Biol. 2017;24:958\u2013968 e955.","journal-title":"Cell Chem Biol"},{"key":"5489_CR46","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/nchembio.2442","volume":"13","author":"H Jiang","year":"2017","unstructured":"Jiang H, Deng R, Yang X, Shang J, Lu S, Zhao Y, Song K, Liu X, Zhang Q, Chen Y, Chinn YE, Wu G, Li J, Chen G, Yu J, Zhang J. Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration. Nat Chem Biol. 2017;13:994\u20131001.","journal-title":"Nat Chem Biol"},{"key":"5489_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2018.09.016","volume":"289","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Zhang L, Hu Y, Jiang K, Li Z, Lin YZ, Wei G, Lu W. Cell-permeable NF-kappaB inhibitor-conjugated liposomes for treatment of glioma. J Control Release. 2018;289:102\u201313.","journal-title":"J Control Release"},{"key":"5489_CR48","doi-asserted-by":"publisher","first-page":"1701070","DOI":"10.1002\/advs.201701070","volume":"5","author":"X He","year":"2018","unstructured":"He X, Chen X, Liu L, Zhang Y, Lu Y, Zhang Y, Chen Q, Ruan C, Guo Q, Li C, Sun T, Jiang C. Sequentially triggered nanoparticles with tumor penetration and intelligent drug release for pancreatic Cancer therapy. Adv Sci (Weinh). 2018;5:1701070.","journal-title":"Adv Sci (Weinh)"},{"key":"5489_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.peptides.2014.04.015","volume":"57","author":"SM Farkhani","year":"2014","unstructured":"Farkhani SM, Valizadeh A, Karami H, Mohammadi S, Sohrabi N, Badrzadeh F. Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules. Peptides. 2014;57:78\u201394.","journal-title":"Peptides."},{"key":"5489_CR50","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/mp.2017.138","volume":"23","author":"K Yalla","year":"2018","unstructured":"Yalla K, Elliott C, Day JP, Findlay J, Barratt S, Hughes ZA, Wilson L, Whiteley E, Popiolek M, Li Y, Dunlop J, Killick R, Adams DR, Brandon NJ, Houslay MD, Hao B, Baillie GS. FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system. Mol Psychiatry. 2018;23:1278\u201386.","journal-title":"Mol Psychiatry"},{"key":"5489_CR51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12964-015-0094-x","volume":"13","author":"YY Sin","year":"2015","unstructured":"Sin YY, Martin TP, Wills L, Currie S, Baillie GS. Small heat shock protein 20 (Hsp20) facilitates nuclear import of protein kinase D1 (PKD1) during cardiac hypertrophy. Cell Commun Signal. 2015;13:16.","journal-title":"Cell Commun Signal."},{"key":"5489_CR52","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.fob.2014.10.011","volume":"4","author":"TP Martin","year":"2014","unstructured":"Martin TP, Hortigon-Vinagre MP, Findlay JE, Elliott C, Currie S, Baillie GS. Targeted disruption of the heat shock protein 20-phosphodiesterase 4D (PDE4D) interaction protects against pathological cardiac remodelling in a mouse model of hypertrophy. FEBS Open Bio. 2014;4:923\u20137.","journal-title":"FEBS Open Bio"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5489-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5489-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5489-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:06:09Z","timestamp":1585008369000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5489-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5489"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5489-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]},"assertion":[{"value":"8 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All protocols involving animals used were approved by the Institutional Animal Care and Use Committee of the University of Washington in accordance with the National Institutes of Health. No ethical approval was required for the cell lines used in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BHL and FWM have financial interests in Portage Pharmaceuticals Ltd. FWM, CMB and GSB are part of Portage Glasgow Limited.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"266"}}